The current subsection explains the in vitro, in vivo, and in silico studies performed for natural products and bioactive molecules derived from them in the management of Alzheimer’s disease via the inhibition of BACE-1 enzymes. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.